Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00518882
Status:
COMPLETED
Last Update Posted:
2017-03-08
First Post:
2007-08-20
Brief Title:
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LEAD-6
Brief Summary:
This trial is conducted in Europe and the United States of America USA The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subjects ongoing OAD oral anti-diabetic drug treatment of either metformin sulphonylurea or a combination of both in subjects with type 2 diabetes Two trial periods A 26 week randomised followed by a 52 week extension 14 38 weeks where all subjects received liraglutide OAD after previous randomisation to either liraglutide or exenatide both combined with OAD treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-006092-21 | EUDRACT_NUMBER | None | None |